Is Retatrutide Better Than Semaglutide? Cross-Trial Reality Check

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 13 sources cited

Investigational drug notice

Retatrutide is an investigational medication. It has not been approved by the FDA for any indication. FormBlends does not sell, supply, prescribe, or facilitate access to retatrutide. The data discussed below comes from published clinical trials. This page is informational. Anyone seeking weight-loss pharmacotherapy should work with a licensed clinician using FDA-approved options.

Key Takeaways

• Retatrutide phase 2 (Jastreboff et al., NEJM 2023): 24.2% mean weight loss at 12 mg over 48 weeks in 338 adults with obesity
• Semaglutide STEP 1 (Wilding et al., NEJM 2021): 14.9% mean weight loss at 2.4 mg over 68 weeks in 1,961 adults
• The cross-trial gap looks large (~9 percentage points), but the two trials are not directly comparable: different populations, different durations, different dose schedules
• No head-to-head trial has been published. Phase 3 retatrutide trials (TRIUMPH program) use placebo as comparator, not semaglutide
• Semaglutide is FDA-approved (Wegovy, Ozempic). Retatrutide is not approved and not legally available outside clinical trials as of May 2026

Direct answer

Cross-trial, retatrutide produced more weight loss in its 48-week phase 2 trial than semaglutide produced in the 68-week STEP 1 trial (24.2% vs 14.9% at top doses). That is not the same as saying retatrutide is "better" in a clinical sense. The trials enrolled different populations, ran different durations, and were never designed to be compared. Phase 2 effect sizes typically compress in phase 3. Retatrutide is also investigational; semaglutide is approved and prescribable today. The honest answer is: the early evidence is more promising for retatrutide, but more promising is not the same as proven.

Table of contents

1. The two trials, side by side
2. What "cross-trial comparison" can and cannot tell you
3. Mechanism: why a triple agonist might outperform a single agonist
4. The dose-response curves
5. Adverse events: similar profile, different magnitudes
6. Duration mismatch: 48 weeks vs 68 weeks
7. The phase 2 to phase 3 effect-size question
8. What the absence of a head-to-head trial means
9. Decision framework: waiting vs starting
10. The contrary view: why semaglutide might still be the better choice
11. FAQ
12. Sources

The two trials, side by side

	Retatrutide phase 2	Semaglutide STEP 1
Primary citation	Jastreboff et al. NEJM 2023	Wilding et al. NEJM 2021
Sample size	338 randomized	1,961 randomized
Duration	48 weeks	68 weeks
Top dose tested	12 mg weekly	2.4 mg weekly
Mean weight loss at top dose	24.2%	14.9%
Mean weight loss at next dose down	22.8% at 8 mg	(only one obesity-indicated dose)
Placebo arm weight loss	2.1%	2.4%
Population	BMI ≥ 30, or BMI ≥ 27 with comorbidity	BMI ≥ 30, or BMI ≥ 27 with comorbidity (non-diabetic)
Mean baseline BMI	37.3	37.9
Trial phase	Phase 2	Phase 3 pivotal
FDA status	Not approved	Approved (Wegovy June 2021)

What "cross-trial comparison" can and cannot tell you

A cross-trial comparison is what you do when you cannot get a head-to-head trial. You line up the two papers, you note the differences in design and population, and you describe the gap between the headline numbers with appropriate caveats.

What it can tell you: the order of magnitude of efficacy in each trial, the qualitative shape of the dose-response curve, the broad adverse event profile, the rough size of the placebo arm response (a sanity check that the trial populations behaved similarly).

What it cannot tell you: whether the same patient would lose more weight on drug A versus drug B. That requires randomization to one or the other inside a single trial. Cross-trial differences can reflect any of the design variables, not just the drugs themselves. A clinician comparing efficacy across trials is making a judgment call, not reading off a definitive answer.

The placebo arms in these two trials produced similar weight loss (2.1% vs 2.4%), which is reassuring. It suggests the trial populations were not radically different in their underlying lifestyle response. That partial alignment supports treating the cross-trial gap as a real signal, though the magnitude estimate stays uncertain.

Mechanism: why a triple agonist might outperform a single agonist

Semaglutide is a GLP-1 receptor agonist. It mimics the natural incretin hormone GLP-1, which slows gastric emptying, increases satiety, reduces glucagon secretion in response to glucose, and stimulates insulin release in a glucose-dependent way.

Retatrutide adds two more receptor targets:

• GIP receptor agonism. Similar to tirzepatide. GIP appears to amplify the satiety and glucose-handling effects of GLP-1. The mechanism is not fully resolved; some hypotheses involve hypothalamic appetite circuits, others involve adipocyte signaling.
• Glucagon receptor agonism. This is the novel addition. Glucagon classically raises blood sugar, which sounds counterproductive. But glucagon also increases energy expenditure (basal metabolic rate goes up), increases hepatic fatty acid oxidation, and has anorectic effects centrally. The trick of a triple agonist is balancing the glucose-raising effect of glucagon against the glucose-lowering effects of GLP-1 and GIP, then capturing the energy-expenditure benefit.

If the mechanistic story holds, retatrutide should produce extra weight loss through metabolic rate effects that single GLP-1 agonists do not access. The phase 2 data is consistent with this. Whether the magnitude holds in phase 3, and whether the metabolic effects come with offsetting safety signals, is what TRIUMPH will reveal.

The dose-response curves

The retatrutide phase 2 trial tested multiple doses, which is useful for understanding the shape of the response.

Retatrutide dose	Mean weight loss at 48 weeks
Placebo	2.1%
1 mg	8.7%
4 mg	17.1%
8 mg	22.8%
12 mg	24.2%

The curve flattens between 8 mg and 12 mg. The jump from 8 to 12 mg adds only 1.4 percentage points despite a 50% dose increase. This matters for two reasons. First, it suggests an effective dose ceiling somewhere in that range, beyond which more drug yields diminishing returns. Second, the side-effect burden generally scales with dose, so the 8 mg dose may end up being the practical sweet spot if phase 3 confirms the pattern.

Semaglutide has a simpler dose-response. Wegovy is approved at 2.4 mg as the maintenance dose for obesity, with a standard titration schedule (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg over 16 weeks). Higher semaglutide doses (up to 7.2 mg weekly) have been tested in the STEP UP trial program and produced larger weight loss (around 21% at 7.2 mg in some readouts), which complicates the cross-trial comparison further: a hypothetical high-dose semaglutide might close more of the gap than the 2.4 mg comparison suggests.

Adverse events: similar profile, different magnitudes

Both drugs share the GLP-1 class adverse event profile.

Event	Retatrutide 12 mg	Semaglutide 2.4 mg (STEP 1)
Nausea	~36% across active doses	~44%
Diarrhea	~27%	~31%
Vomiting	~16%	~24%
Discontinuation for adverse events	6-12% across arms	~7%
Heart rate increase	~3-4 bpm at top doses	~3 bpm

The headline takeaway: the qualitative profile is the same family of side effects. Phase 2 retatrutide did not show new adverse event categories beyond what GLP-1 and dual-agonist drugs have shown. The 48-week duration is too short to detect rare or long-latency events. Phase 3 trials (TRIUMPH-1 through TRIUMPH-5) running 72 weeks or longer should clarify safety with more confidence.

Duration mismatch: 48 weeks vs 68 weeks

STEP 1 ran 68 weeks; retatrutide phase 2 ran 48 weeks. Semaglutide weight loss in STEP 1 reached approximately 10.6% at 48 weeks and continued losing through week 68. If you compare drugs at matched timepoints (48 weeks), the gap is roughly 24.2% retatrutide vs ~10.6% semaglutide, which actually widens the apparent gap.

But the retatrutide curve at 48 weeks had not plateaued either. If retatrutide had been allowed to run to 68 weeks, the most likely scenario is that mean weight loss would have continued increasing, possibly to 27-30% range, possibly higher. That projection is speculative. It is supported by the shape of the curve but not by direct data.

The reasonable summary: at any matched timepoint between 24 and 48 weeks, retatrutide phase 2 shows a substantially larger effect than STEP 1 semaglutide. Whether that gap holds at longer durations is unknown.

The phase 2 to phase 3 effect-size question

Drug development has a well-documented pattern: phase 2 trials tend to produce larger effect sizes than phase 3 trials of the same drug at the same dose. The phenomenon has several drivers. Phase 2 populations are smaller and more carefully selected. Phase 2 trial sites tend to be experienced specialty centers with high adherence rates. Phase 2 protocols allow more flexibility in dose titration and supportive care. Phase 3 trials add more sites, broader patient populations, and lower-touch administration, all of which reduce the average effect.

The retatrutide phase 3 TRIUMPH program is running across more sites and broader populations than the phase 2. The published phase 2 effect of 24.2% at 12 mg might compress to 20-22% in phase 3. It might also hold. The directional point is that the cross-trial gap with semaglutide is most likely to narrow somewhat, not widen, when phase 3 results read out.

What the absence of a head-to-head trial means

The phase 3 TRIUMPH-3 trial includes tirzepatide as an active comparator, not semaglutide. There is no announced retatrutide-vs-semaglutide head-to-head study. This is normal for a drug in late-stage development; head-to-head trials against approved competitors are usually post-approval studies, often funded by the new drug's sponsor and run for marketing rather than regulatory reasons.

For a patient or clinician reading the literature in 2026, the practical implication is that any "retatrutide is X percent better than semaglutide" framing should be treated as a cross-trial estimate with substantial uncertainty bands. Anyone presenting the comparison with high confidence is overstating the evidence.

Decision framework: waiting vs starting

If you meet criteria for obesity pharmacotherapy today: starting semaglutide (or tirzepatide) now is usually the better clinical choice than waiting for retatrutide. Untreated obesity has ongoing metabolic and cardiovascular cost. The expected delay until retatrutide approval is 2027 or later, which is real time during which an alternative therapy could be working.

If you have already responded well to semaglutide: switching to a hypothetical future retatrutide carries unknown benefit. Switching for the sake of the bigger phase 2 number is a weak rationale. If your response plateaus or you cannot tolerate the side effects, the conversation changes.

If you have plateaued on semaglutide at maximum tolerated dose: the more proximate option is switching to tirzepatide, which is FDA-approved (Zepbound for obesity), has phase 3 data (SURMOUNT-1 showed ~22.5% mean loss at 15 mg), and is prescribable today. Tirzepatide is probably the closest available stand-in for what retatrutide might offer.

If you are a clinician fielding patient questions: the framing that works is "the data so far is promising but early, and it is not yet available outside trials. Here is what we can do with approved options now."

The contrary view: why semaglutide might still be the better choice

The "retatrutide wins on the numbers" framing has real limits. A patient-centered counterargument:

Evidence base. Semaglutide has been in human use since 2017 (FDA approval for diabetes). It has cardiovascular outcome data (SELECT trial, Lincoff et al. NEJM 2023, showing 20% reduction in major adverse cardiovascular events versus placebo in patients with established cardiovascular disease and obesity). Retatrutide has none of that. The phase 2 trial enrolled 338 patients followed for 48 weeks. The long-term safety profile is essentially unknown.

Availability. A drug you can fill at the pharmacy this week is better than a drug that might be approved in 2027. Even if retatrutide eventually outperforms semaglutide in head-to-head data, the patient who waits has lost two or more years of treatment effect, which compounds.

Phase 3 risk. Drugs do fail in phase 3. The retatrutide phase 2 readout is strong, which lowers but does not eliminate the risk of unexpected safety signals or reduced efficacy emerging in larger trials.

Cost and access. If retatrutide is approved, initial pricing will likely match other branded incretin medications. Patient access through insurance and compounding pathways will take years to mature. The first cohort of approved-but-unaffordable patients will face exactly the access problems semaglutide and tirzepatide patients face today.

The honest summary: retatrutide may eventually be the better drug for some patients. Semaglutide is the better available choice for almost everyone who needs treatment now.

FAQ

Is retatrutide stronger than semaglutide? In cross-trial phase 2 versus phase 3 comparison, yes: 24.2% mean weight loss at 12 mg over 48 weeks versus 14.9% at 2.4 mg over 68 weeks. The comparison has limits described above.

When will retatrutide be available? Phase 3 trials (TRIUMPH program) are ongoing. FDA submission and potential approval are projected for 2027 or later. Timelines can slip.

Can I get retatrutide from a compounding pharmacy? No legitimate 503A compounding pharmacy is producing retatrutide for clinical use. The drug is not FDA-approved, and there is no shortage list status that would permit compounding. Any source claiming to sell retatrutide for personal use is operating outside the regulated supply chain.

What is the difference in mechanism? Semaglutide is a single GLP-1 agonist. Retatrutide is a triple agonist of GLP-1, GIP, and glucagon receptors.

Will retatrutide replace semaglutide? Unlikely to fully replace. More likely: retatrutide becomes a higher-efficacy option for patients who need more weight loss than semaglutide produces, similar to how tirzepatide has positioned itself relative to semaglutide.

What are the most common side effects of retatrutide? Gastrointestinal: nausea, diarrhea, vomiting. Dose-dependent in phase 2. Heart rate increase of 3-4 bpm at top doses.

Does retatrutide cause hair loss? Some patients in phase 2 reported hair changes consistent with telogen effluvium associated with rapid weight loss. This is a class effect with any rapid weight reduction, not specific to retatrutide.

Is retatrutide safer than semaglutide? Unknown. Semaglutide has years of post-marketing data. Retatrutide has 48 weeks of phase 2 data in 338 patients. The safety database is not comparable.

What does FormBlends prescribe? FormBlends connects patients with licensed providers who prescribe FDA-approved and compounded semaglutide and tirzepatide where appropriate. FormBlends does not prescribe or supply retatrutide.

Sources

1. Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial. New England Journal of Medicine. 2023;389:514-526.
2. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384:989-1002.
3. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387:205-216.
4. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine. 2023;389:2221-2232.
5. Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide in Type 2 Diabetes: A Phase 2 Trial. The Lancet. 2023;402:529-540.
6. FDA. Wegovy (semaglutide) Prescribing Information. Approved June 2021.
7. FDA. Ozempic (semaglutide) Prescribing Information. Approved December 2017.
8. ClinicalTrials.gov. TRIUMPH-1 through TRIUMPH-5 phase 3 retatrutide program identifiers.
9. Eli Lilly investor materials, 2024-2026.
10. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (SURMOUNT-4). JAMA. 2024.
11. American Association of Clinical Endocrinologists. Obesity Pharmacotherapy Guidelines, 2024 Update.
12. Garvey WT. Clinical Definition of Overweight and Obesity. Endocrine Practice. 2022.
13. Endocrine Society. Clinical Practice Guideline on Pharmacological Management of Obesity, 2024 Update.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with independent licensed providers and U.S.-based pharmacies. We do not prescribe or dispense medication directly. Clinical decisions belong to the patient and provider.

Compounded Medication Notice. Compounded semaglutide is prepared by state-licensed 503A compounding pharmacies in response to individual prescriptions. Compounded medications are not FDA-approved and have not undergone the same review as branded products. They are not interchangeable with Wegovy or Ozempic.

Investigational Drug Notice. Retatrutide is an investigational compound under development by Eli Lilly and Company. It has not received FDA approval for any indication. FormBlends does not sell, supply, or facilitate access to retatrutide. Trial data discussed on this page is from published peer-reviewed literature and is for educational purposes only.

Results Disclaimer. Clinical trial outcomes describe mean responses in study populations. Individual results depend on adherence, baseline weight, lifestyle, comorbidities, and biological variation. Reported trial percentages should not be read as guarantees of personal outcome.

Trademark Notice. Wegovy and Ozempic are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Retatrutide is a development-stage compound from Eli Lilly. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly.